Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

More Than ADAMTS13: The Impact of Area Deprivation on Major Adverse Cardiovascular Events in Ittp Survivors

Senthil Sukumar, Jenna Brown, Marshall Mazepa, Spero Cataland, Shruti Chaturvedi

Blood (2024) 144 (Supplement 1): 140.

https://doi.org/10.1182/blood-2024-211400

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Journal Articles

Impaired Cognitive Function in Immune-TTP Is Better Predicted By Serum Thrombomodulin Than ADAMTS13 Activity: Results of a Longitudinal Multicenter Pilot Study

Aaron Boothby, Michael D Evans, Shangbin Yang, Senthil Sukumar, James G Scott, Deirdra Terrell, Spero Cataland, Marshall Mazepa

Blood (2023) 142 (Supplement 1): 1258.

https://doi.org/10.1182/blood-2023-181094

Published: 2023

Journal Articles

Thrombotic Thrombocytopenic Purpura (TTP) Survivors Exhibit Impaired Stress Perfusion on Cardiac MRI

Senthil Sukumar, Leah Danish, Ang Li, Yuchi Han, Spero Cataland

Blood (2023) 142 (Supplement 1): 696.

https://doi.org/10.1182/blood-2023-186331

Published: 2023

Journal Articles

Genetic Landscape of Thrombotic Microangiopathies with Focus on Plasminogen Mutation Variants

Shreya Agarwal, Senthil Sukumar, Camila Masias, Spero Cataland

Blood (2023) 142 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2023-187248

Published: 2023

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Fatigue and Cognition During Remission in Adults with Immune Thrombotic Thrombocytopenic Purpura

Shannon M Reeves, Amanda J Llaneza, Sara K. Vesely, Janna Journeycake, Mohamad O. Khawandanah, Marshall Mazepa, Frank Akwaa, Adam Cuker, Shruti Chaturvedi, Neil Zakai, Ming Yeong Lim, Radhika Gangaraju, San Keller, Spero Cataland, Deirdra R Terrell

Blood (2022) 140 (Supplement 1): 1228–1229.

https://doi.org/10.1182/blood-2022-170139

Published: 2022

Journal Articles

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura

Hridaya Shah, Ann Kim, Senthil Sukumar, Marshall Mazepa, Ruhail Kohli, Evan M. Braunstein, Robert A. Brodsky, Spero Cataland, Shruti Chaturvedi

Blood (2022) 139 (16): 2570–2573.

https://doi.org/10.1182/blood.2022015545

Published: 2022

Includes: Supplemental data

Journal Articles

Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors

Deirdra Terrell, Rachel Ann Kelley, Amanda J Llaneza, Sara K. Vesely, Janna Journeycake, Mohamad O. Khawandanah, Marshall Mazepa, Frank Akwaa, Adam Cuker, Shruti Chaturvedi, Neil A. Zakai, Ming Yeong Lim, Radhika Gangaraju, Spero Cataland

Blood (2021) 138 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2021-153407

Published: 2021

Journal Articles

Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies

Bradley P. Dixon, Alvaro Domingo Madris-Aris, Brigitte Adams, David Kavanagh, Hee Gyung Kang, Jimmy Wang, Katherine Garlo, Kazuki Tanaka, Laurence Greenbaum, Masayo Ogawa, Nils Heyne, Seong Heon Kim, Spero Cataland, Sung-Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff-Luett

Blood (2021) 138 (Supplement 1): 769.

https://doi.org/10.1182/blood-2021-145040

Published: 2021

Journal Articles

Creating Clinical Meaning for the Promis Cognitive Function Abilities Instrument: Improving Remission Outcomes for Adults with Thrombotic Thrombocytopenic Purpura

Deirdra Terrell, Kalyn Neighbors, Amanda J Llaneza, Rachel Ann Kelley, Sara K. Vesely, Janna Journeycake, Mohamad O. Khawandanah, Marshall Mazepa, Frank Akwaa, Adam Cuker, Shruti Chaturvedi, Neil A. Zakai, Ming Yeong Lim, Radhika Gangaraju, San Keller, Spero Cataland

Blood (2021) 138 (Supplement 1): 834.

https://doi.org/10.1182/blood-2021-153720

Published: 2021

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors

Senthil Sukumar, MD, Max Brodsky, MD, Sarah Hussain, Spero Cataland, Shruti Chaturvedi, MBBS,MS

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138551

Published: 2020

Journal Articles

Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias, MDMPH, Shangbin Yang, PhD, Senthil Sukumar, MD, Alcinda Flowers, MD, Haiwa Wu, Krista Carter, Shili Lin, Chenggon Han, Spero Cataland

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142117

Published: 2020

Journal Articles

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Blood (2020) 136 (19): 2103–2117.

https://doi.org/10.1182/blood.2020005221

Published: 2020

Includes: Supplemental data

Journal Articles

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias, MDMPH, Rawan Tarawneh, MD, Haiwa Wu, Krista Carter, Shangbin Yang, PhD, Alcinda Flowers, MD, Marie Scully, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 2377.

https://doi.org/10.1182/blood-2019-130369

Published: 2019

Journal Articles

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Deirdra Terrell, PhD, Spero Cataland, MD, Laura Beebe, PhD, San Keller, PhD MS, Julie Panepinto, MDMSPH, Sara K. Vesely, PhD MPH, James George, MD, Rachel Ann Kelley, BS, Marshall Cheney, PhD

Blood (2019) 134 (Supplement_1): 931.

https://doi.org/10.1182/blood-2019-128989

Published: 2019

Journal Articles

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Blood (2019) 134 (Supplement_1): 90.

https://doi.org/10.1182/blood-2019-129383

Published: 2019

NARROW

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

More Than ADAMTS13: The Impact of Area Deprivation on Major Adverse Cardiovascular Events in Ittp Survivors

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Impaired Cognitive Function in Immune-TTP Is Better Predicted By Serum Thrombomodulin Than ADAMTS13 Activity: Results of a Longitudinal Multicenter Pilot Study

Thrombotic Thrombocytopenic Purpura (TTP) Survivors Exhibit Impaired Stress Perfusion on Cardiac MRI

Genetic Landscape of Thrombotic Microangiopathies with Focus on Plasminogen Mutation Variants

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Fatigue and Cognition During Remission in Adults with Immune Thrombotic Thrombocytopenic Purpura

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura

Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors

Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies

Creating Clinical Meaning for the Promis Cognitive Function Abilities Instrument: Improving Remission Outcomes for Adults with Thrombotic Thrombocytopenic Purpura

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors

Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only